Legend Biotech Corp (NASDAQ:LEGN) reported disappointing first-quarter results, with losses of 3 cents per share, missing analysts’ expectations of 2 cents. The company also fell short on sales, reporting $305.1 million versus an expected $307.035 million. Despite the underperformance, shares rose 1.3% to $28.63. Analysts have adjusted their price targets: RBC Capital maintained an Outperform rating, raising the target to $64, while Morgan Stanley upheld an Overweight rating but lowered the target to $48. TD Cowen kept a Hold rating and increased the target to $29.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52538113/these-analysts-revise-their-forecasts-on-legend-biotech-after-q1-results
